ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 67 filers reported holding ORIC PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,982,234 | -9.3% | 1,649,956 | +16.4% | 0.12% | 0.0% |
| Q2 2023 | $11,002,694 | +654.8% | 1,417,873 | +454.4% | 0.12% | +611.8% |
| Q1 2023 | $1,457,672 | -52.7% | 255,732 | -51.1% | 0.02% | -54.1% |
| Q4 2022 | $3,081,401 | +77.1% | 523,158 | -3.8% | 0.04% | +76.2% |
| Q3 2022 | $1,740,000 | -69.7% | 543,812 | -57.6% | 0.02% | -68.2% |
| Q2 2022 | $5,749,000 | -16.1% | 1,283,158 | 0.0% | 0.07% | +10.0% |
| Q1 2022 | $6,852,000 | -75.5% | 1,283,158 | -32.4% | 0.06% | -73.2% |
| Q4 2021 | $27,921,000 | +6.9% | 1,899,391 | +52.0% | 0.22% | +9.8% |
| Q3 2021 | $26,131,000 | +44.6% | 1,249,707 | +22.3% | 0.20% | +50.0% |
| Q2 2021 | $18,077,000 | -28.1% | 1,021,898 | -0.5% | 0.14% | -27.7% |
| Q1 2021 | $25,156,000 | -29.4% | 1,026,783 | -2.5% | 0.19% | -31.9% |
| Q4 2020 | $35,640,000 | +43.2% | 1,052,879 | +5.8% | 0.28% | +16.5% |
| Q3 2020 | $24,895,000 | +181.9% | 995,382 | +280.2% | 0.24% | +160.4% |
| Q2 2020 | $8,830,000 | – | 261,778 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 602,272 | $3,643,746 | 14.84% |
| Column Group LLC | 3,568,181 | $21,587,495 | 14.33% |
| Nextech Invest Ltd. | 4,285,714 | $25,928,570 | 7.86% |
| Prosight Management, LP | 2,579,802 | $15,607,802 | 4.95% |
| Invus Financial Advisors, LLC | 1,007,575 | $6,095,829 | 3.82% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,123,345 | $6,796,237 | 2.06% |
| VR Adviser, LLC | 2,142,856 | $12,964,279 | 1.36% |
| Altium Capital Management LP | 418,706 | $2,533,171 | 1.32% |
| Euclidean Capital LLC | 1,978,820 | $11,971,862 | 1.31% |
| Frazier Life Sciences Management, L.P. | 2,142,855 | $12,964,273 | 0.86% |